The proportion of people with heart failure receiving optimal therapy increased significantly with expansion of this initiative within a general cardiology practice.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

The study involved 207 subjects across sites in Canada and the US, who underwent VT ablation using the company’s ULTC system.

Efficacy of tirzepatide does not differ significantly between men and women, despite sex-specific differences in ...

Ejection fraction (EF) measures how well the heart pumps blood. A normal EF is 55% to 70%, meaning the heart pumps out at least half of the blood in its left ventricle with each beat. An EF below 50% ...

Please provide your email address to receive an email when new articles are posted on . Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients ...

The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company ...

Background Diabetes mellitus (DM) is a common comorbidity in hypertrophic cardiomyopathy (HCM) and may exacerbate arrhythmic ...

Partnership further supports trial recruitment; FORTITUDE-HCM to be highlighted at upcoming HCMA Annual Patient MeetingEnrollment underway for ...

A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack— doesn’t benefit the vast majority of patients and may contribute to a higher risk of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...